Skip to main content
    C

    Castle Biosciences Inc (CSTL)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $33.79
    -0.71 (-2.06%)

    Market Cap: $1.04B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Castle Biosciences Inc (CSTL) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Castle Biosciences reported revenue of $344.23M for the fiscal year ended Dec 31, 2025, up 3.7% from the year before. That year, net income was -$24.16M with a net margin of -7.0%, operating cash flow was $64.35M and free cash flow was $28.33M. The quarter ended Sep 30, 2026 had revenue of $102.89M and net income of -$4.10M.

    Revenue and Margins

    The operating margin was -12.4% in the fiscal year ended Dec 2025. Over the 8 years to Dec 2025, revenue grew from $13.75M, a compound annual rate of 49.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$344.23M+3.7%79.4%-12.4%-7.0%
    Dec 2024$332.07M+51.1%81.9%2.6%5.5%
    Dec 2023$219.79M+60.4%79.5%-30.9%-26.1%
    Dec 2022$137.04M+45.7%76.6%-53.2%-49.0%
    Dec 2021$94.08M+50.2%83.2%-42.6%-33.3%
    Dec 2020$62.65M+20.8%84.5%-10.4%-16.4%
    Dec 2019$51.87M+127.6%85.9%14.1%10.2%
    Dec 2018$22.79M+65.7%76.8%-16.8%-27.9%
    Dec 2017$13.75MN/A64.2%-79.2%-89.9%
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$344.23M$332.07M$219.79M$137.04M$94.08M$62.65M$51.87M$22.79M$13.75M
    Cost of revenue$71.03M$60.20M$44.98M$32.01M$15.82M$9.69M$7.31M$5.30M$4.92M
    Gross profit$273.20M$271.86M$174.81M$105.03M$78.26M$52.96M$44.55M$17.49M$8.83M
    Research and development$51.85M$52.04M$53.62M$44.90M$29.65M$13.26M$7.38M$4.85M$4.47M
    Operating income-$42.81M$8.67M-$67.98M-$72.86M-$40.08M-$6.54M$7.33M-$3.84M-$10.90M
    Net income-$24.16M$18.25M-$57.47M-$67.14M-$31.29M-$10.28M$5.28M-$6.37M-$12.37M
    EBITDA-$6.11M$17.98M-$61.14M-$63.68M-$36.67M-$5.23MN/A-$3.76M-$10.40M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$102.89M$103.55M$83.68M$87.01M$83.04M$86.19M$87.99M$86.31M$85.78M$87.00M$72.97M$66.12M
    Gross profit$78.97M$79.85M$63.15M$68.69M$64.34M$68.56M$71.61M$70.13M$70.17M$72.48M$59.08M$53.70M
    Operating income-$2.73M-$3.07M-$18.41M-$3.83M-$6.80M-$4.25M-$27.93M$4.05M$5.08M$5.01M-$5.47M-$5.66M
    Net income-$4.10M-$2.06M-$14.52M-$2.33M-$501.00K$4.52M-$25.85M$9.59M$2.27M$8.92M-$2.53M-$2.58M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $10.06M by $106.67M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$578.56M$531.24M$453.34M$447.33M$462.57M$439.33M$119.75M$22.40M$9.82M
    Current assets$361.10M$360.15M$295.63M$292.29M$353.74M$429.59M$116.68M$18.13M$6.68M
    Cash and equivalents$116.73M$119.71M$98.84M$122.95M$329.63M$409.85M$98.84M$4.48M$1.21M
    Total liabilities$107.68M$75.40M$62.07M$48.18M$50.83M$23.64M$34.63M$32.47M$24.09M
    Short-term debt$417.00K$278.00K$0$1.78M$1.18M$5.83M$5.83M$0$1.00M
    Long-term debt$9.64M$9.74M$0N/AN/AN/A$19.29M$24.50M$17.60M
    Shareholder equity$470.87M$455.83M$391.27M$399.15M$411.74M$415.69M$85.11M-$56.57M-$14.27M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$579.41M$561.18M$547.80M$578.56M$562.79M$544.73M$501.71M$531.24M$514.57M$487.31M$458.51M$453.34M
    Total liabilities$100.96M$91.15M$86.39M$107.68M$95.74M$89.35M$61.41M$75.40M$73.51M$63.42M$56.05M$62.07M
    Cash and equivalents$77.99M$62.12M$63.76M$116.73M$85.56M$82.23M$89.69M$119.71M$94.96M$85.57M$82.95M$98.84M
    Shareholder equity$478.44M$470.03M$461.42M$470.87M$467.05M$455.38M$440.31M$455.83M$441.06M$423.89M$402.46M$391.27M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 44.0% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow$64.35M$64.87M-$5.63M-$41.66M-$18.98M$9.87M$7.01M-$12.29M-$12.23M
    Capital expenditures$36.02M$28.33M$13.62M$5.63M$3.48M$4.75M$937.00K$277.04K$494.85K
    Free cash flow$28.33M$36.54M-$19.25M-$47.29M-$22.47M$5.11M$6.08M-$12.57M-$12.73M
    Dividends paidN/AN/AN/A$1.69M$3.12MN/AN/A$0$0
    Share repurchasesN/AN/AN/AN/A$336.00K$0N/AN/AN/A
    Investing cash flow-$60.37M-$50.14M-$16.18M-$166.54M-$66.66M-$4.75M-$937.00K-$277.04K-$494.85K
    Financing cash flow-$6.96M$6.14M-$2.30M$1.51M$5.42M$305.89M$88.29M$15.84M$8.87M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$19.74M$15.20M-$22.13M$26.93M$22.63M$20.82M-$6.04M$24.36M$23.34M$24.00M-$6.83M$18.59M
    Capital expenditures$7.49M$8.65M$12.46M$7.18M$14.83M$9.26M$4.74M$7.57M$6.38M$5.23M$9.15M$3.79M
    Free cash flow$12.25M$6.55M-$34.58M$19.75M$7.80M$11.56M-$10.78M$16.80M$16.96M$18.77M-$15.99M$14.79M
    Last 12 quarters

    Frequently Asked Questions About CSTL

    What is Castle Biosciences' annual revenue?

    Castle Biosciences reported revenue of $344.23M for the fiscal year ended Dec 31, 2025.

    How fast is Castle Biosciences' revenue growing?

    Revenue was up 3.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 35.9%.

    Is Castle Biosciences profitable?

    No. Castle Biosciences reported net income of -$24.16M for the fiscal year ended Dec 31, 2025, with a net margin of -7.0%.

    How much free cash flow does CSTL generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $64.35M minus capital expenditures of $36.02M produced free cash flow of $28.33M.

    How much debt does Castle Biosciences have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $9.64M, short-term debt of $417.00K and cash and equivalents of $116.73M.